As Aidence, we are proud to announce we have completed a €10 million Series A funding round. The round was led by INKEF Capital and co-investor Rabo Ventures, alongside our existing investors Northzone, HenQ and Health Innovations. This investment brings Aidence’s total funding to €12.5 million.
Aidence was founded in Amsterdam in 2015 by Mark-Jan Harte (CEO) and Jeroen van Duffelen (CBO). Since then, the company has made waves in the medical imaging industry with its AI solution, Veye Lung Nodules.
Lung cancer is one of the most common cancers worldwide, and early detection is of great importance for survival. Aidence’s AI-enabled pulmonary nodule management assistant, Veye Lung Nodules, connects with existing imaging infrastructure and enables radiologists to better spot and track changes in pulmonary nodules. Veye Lung Nodules is already installed in more than 10 hospitals in the Netherlands, United Kingdom, and Scandinavia and processes hundreds of studies per week.
Aidence was selected for SBRI Healthcare last year, a UK National Health Service (NHS) innovation initiative. Its health economics team recognised Veye Lung Nodules has the potential to provide relief to the pressures in the radiologist workforce and reduce the number of missed lung cancers. At the European Congress of Radiology (ECR), Europe’s largest radiology show in Vienna later this month, the world-renowned Royal Infirmary of Edinburgh hospital and the Edinburgh imaging facility QMRI will also present four abstracts as a result of the collaboration on clinical validation for Veye Lung Nodules.
Mark-Jan Harte, Aidence CEO, said:
Since day one, we have been determined to deliver a tangible clinical AI solution that can be used by healthcare professionals to help their patients. We welcome INKEF and Rabo Ventures on our journey as we strive to shape the future of the medical imaging industry.
With this funding, we will continue building our European market expansion while also building towards FDA clearance giving us access to the US healthcare market. This investment will allow our research and development team to expand and explore new avenues for the Veye platform to support our radiologist AI pioneers and the patients they care for.
Our stellar team is a mix of data scientists, software engineers, and medical industry professionals. In the coming months, we look forward to expanding our technical and commercial teams to achieve growth and make an impact on medical professionals and patients.
*Note: Veye Lung Nodules was known as Veye Chest at the time of the investment.
